190 related articles for article (PubMed ID: 23832765)
1. TrkC promotes survival and growth of leukemia cells through Akt-mTOR-dependent up-regulation of PLK-1 and Twist-1.
Kim MS; Kim GM; Choi YJ; Kim HJ; Kim YJ; Jin W
Mol Cells; 2013 Aug; 36(2):177-84. PubMed ID: 23832765
[TBL] [Abstract][Full Text] [Related]
2. c-Src activation through a TrkA and c-Src interaction is essential for cell proliferation and hematological malignancies.
Kim MS; Kim GM; Choi YJ; Kim HJ; Kim YJ; Jin W
Biochem Biophys Res Commun; 2013 Nov; 441(2):431-7. PubMed ID: 24369899
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
4. Effects of endoplasmic reticulum stress on autophagy and apoptosis of human leukemia cells via inhibition of the PI3K/AKT/mTOR signaling pathway.
Li LJ; Chai Y; Guo XJ; Chu SL; Zhang LS
Mol Med Rep; 2018 Jun; 17(6):7886-7892. PubMed ID: 29620275
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway.
Yu C; Mao X; Li WX
Biochem Biophys Res Commun; 2005 Jun; 331(2):391-7. PubMed ID: 15850772
[TBL] [Abstract][Full Text] [Related]
6. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.
Yoshimi A; Goyama S; Watanabe-Okochi N; Yoshiki Y; Nannya Y; Nitta E; Arai S; Sato T; Shimabe M; Nakagawa M; Imai Y; Kitamura T; Kurokawa M
Blood; 2011 Mar; 117(13):3617-28. PubMed ID: 21289308
[TBL] [Abstract][Full Text] [Related]
7. NTRK3 exhibits a pro-oncogenic function in upper tract urothelial carcinomas.
Lim LM; Lee YC; Lin TW; Hong ZX; Hsu WC; Ke HL; Hwang DY; Chung WY; Li WM; Lin HH; Kuo HT; Huang AM
Kaohsiung J Med Sci; 2024 May; 40(5):445-455. PubMed ID: 38593276
[TBL] [Abstract][Full Text] [Related]
8. Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways.
Yang L; Hou Y; Yuan J; Tang S; Zhang H; Zhu Q; Du YE; Zhou M; Wen S; Xu L; Tang X; Cui X; Liu M
Oncotarget; 2015 Sep; 6(28):25755-69. PubMed ID: 26342198
[TBL] [Abstract][Full Text] [Related]
9. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis.
Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Cappellini A; Ognibene A; McCubrey JA
Biochim Biophys Acta; 2010 Sep; 1803(9):991-1002. PubMed ID: 20399811
[TBL] [Abstract][Full Text] [Related]
11. Thymoquinone induces cytotoxicity and reprogramming of EMT in gastric cancer cells by targeting PI3K/Akt/mTOR pathway.
Feng LM; Wang XF; Huang QX
J Biosci; 2017 Dec; 42(4):547-554. PubMed ID: 29229873
[TBL] [Abstract][Full Text] [Related]
12. c-Src is required for tropomyosin receptor kinase C (TrkC)-induced activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway.
Jin W; Yun C; Jeong J; Park Y; Lee HD; Kim SJ
J Biol Chem; 2008 Jan; 283(3):1391-1400. PubMed ID: 17991742
[TBL] [Abstract][Full Text] [Related]
13. The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway.
Guo Y; Li Y; Wang FF; Xiang B; Huang XO; Ma HB; Gong YP
Int J Biochem Cell Biol; 2019 Jan; 106():8-20. PubMed ID: 30389549
[TBL] [Abstract][Full Text] [Related]
14. [Down-regulatory effect of Nucleostemin expression on signal molecule of PI3K/AKT/mTOR pathway in HL-60 cells].
Jia Y; Wei YY; Zhang F; Li ZB; Liu S; Yue BH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):25-9. PubMed ID: 24598645
[TBL] [Abstract][Full Text] [Related]
15. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of miR-122-5p regulating the activation of PI3K-Akt-mTOR signaling pathway on the cell proliferation and apoptosis of osteosarcoma cells through targeting TP53 gene.
Li KW; Wang SH; Wei X; Hou YZ; Li ZH
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12655-12666. PubMed ID: 33378012
[TBL] [Abstract][Full Text] [Related]
17. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination.
Yu JS; Cui W
Development; 2016 Sep; 143(17):3050-60. PubMed ID: 27578176
[TBL] [Abstract][Full Text] [Related]
18. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
19. Low-dose arsenic-mediated metabolic shift is associated with activation of Polo-like kinase 1 (Plk1).
Li Z; Lu Y; Ahmad N; Strebhardt K; Liu X
Cell Cycle; 2015; 14(19):3030-9. PubMed ID: 26292025
[TBL] [Abstract][Full Text] [Related]
20. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
